Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Oakmark Global Fund David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz | “Sugi Holdings ($7649.T) is a new long initiation comprising 1.8% of the fund. The company operates one of Japan's leading retail drugstore chains, differentiated by a nationwide network of dispensing pharmacies integrated directly within its retail stores. Oakmark's investment thesis focuses on the market's failure to recognize Sugi's durable organic growth runway, disciplined consolidation strategy, and technological modernization. The business benefits from an enduring structural tailwind in Japan's aging demographic, which fuels stable recurring prescription demand and non-discretionary consumer healthcare spending. Founder-led management continues to generate high returns on invested capital via accretive roll-up acquisitions in a fragmented dispensing pharmacy landscape. Additionally, internal adoption of automated inventory and AI customer engagement systems provides unit-level operating leverage and margin expansion. Upcoming catalysts involve further bolt-on M&A, cross-selling synergies from strategic partnerships, and ongoing market share gains. Key investment risks include Japanese government drug price revisions (NHI pricing cuts), labor shortages for certified pharmacists, and intensifying retail drugstore competition.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Oakmark Fund International Small Cap David G. Herro | “Sugi Holdings ($7649.T) is a prominent Japanese pharmacy and drugstore chain operator, comprising 2.8% of the fund's portfolio. The manager remains bullish despite short-term share price weakness, viewing the market's negative reaction to equity dilution as an overreaction that ignores the strategic benefits of partnering with sovereign wealth fund GIC to pursue market consolidation. Economically, pharmacy chains rely on geographic density and purchasing scale to optimize wholesale unit economics and preserve retail pricing power. Japan's fragmented retail pharmacy and dispensing industry offers an attractive consolidation backdrop, where scale advantages enhance operating leverage and sustain high returns on invested capital across store footprints. Key catalysts include accretive merger and acquisition deployments backed by GIC capital and ongoing healthy same-store sales growth. Primary risks include integration headwinds from regional acquisitions and ongoing regulatory pricing revisions in Japanese healthcare dispensing.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
